Investors & Media

November 5, 2026

Immutep Announces Upcoming Poster Presentations at CTOS 2026 and ESMO Immuno-Oncology & Advanced Therapies Congress 2026

October 29, 2026

Immutep Quarterly Activities Report Q1 FY27

October 28, 2026

Immutep Receives A$2.16 million French R&D Tax Incentive

October 23, 2026

Immutep Announces Presentation of Quality of Life Data from EFTISARC-NEO Phase II Trial at ESMO 2026

October 19, 2026

Immutep Announces Late-Breaking Abstract on IMP761 Accepted for Poster Presentation at ACR Convergence 2026

October 14, 2026

Immutep and Monash University Secure Further ARC Linkage Projects Funding for LAG-3 Research

October 23, 2026

ESMO Congress 2026 – EFTISARC-NEO (Soft Tissue Sarcoma)

August 20, 2026

Immutep Corporate Presentation

June 4, 2026

EULAR 2026 – IMP761, a novel immunosuppressive LAG-3 agonist antibody in the clinic

May 31, 2026

ASCO 2026 – Eftilagimod alfa, an APC activator via MHC class II, induced lymphocyte activation linked to improved survival in metastatic cancer patients

February 20, 2026

Immutep Corporate Presentation

December 2, 2025

SABCS 2025 – Optimal biological dose of eftilagimod alpha, a soluble LAG-3 protein, in metastatic breast cancer patients receiving weekly paclitaxel in AIPAC-003